Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Obesity

Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet

Skye stock plunged Monday after the biotech company scrapped its failed eye-disease drug in favor of pivoting to obesity treatment.

Investors Business Daily

Eating ultra-processed food linked to chronic insomnia, study finds

The consumption of UPF is on the rise worldwide, and it has been linked to diabetes, obesity and cancer

Evening Standard

Abbott Snags U.S. Clearance To Enter The Obesity Arena, Rivaling Dexcom

Abbott Laboratories gained U.S. clearance Monday for a pair of new CGMs. But Abbott stock fell a fraction at the close.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Economic development in sub-Saharan Africa is linked to increasing obesity rates in women

Obesity and excess weight gain, traditionally perceived as health issues predominantly affecting high-income countries, are now increasingly prevalent in low and middle-income regions.

The Conversation

Higher Stroke Risk For Women Overweight In Teenage Or Young Adult Years: Study

The researchers found that having excess body weight at age 14 or 31 raises the risk of ischemic stroke in women by the age of 55.

Medical Daily

Structure Therapeutics vs. Viking Therapeutics: Which Weight-Loss Drug Stock Wins?

With weight-loss drugs gaining traction, which biopharma stock wins?

Barchart

Latino adults in the U.S. will be most at risk of cardiovascular disease by 2050

The American Heart Association also revealed that Hispanic children are projected to have the highest obesity rates

Latin Times

Read news from The Economist, FT, and more,
with one subscription

Ozempic may improve taste buds

A proof-of-concept study found that semaglutide may influence taste perception of sweet compounds

Salon

Obesity Drug Leader In Buy Zone After Huge Gains

Novo Nordisk is in a buy zone after a 39% gain year to date. The anti-obesity drug market is expect to grow to $4.4 billion by 2032.

Investors Business Daily

More Than Half Of Americans Will Develop Cardiovascular Disease In 30 Years: Report

Around 61% of U.S. adults are expected to have some type of cardiovascular disease within the next 30 years, according to a recent report from the American Heart Association.

Medical Daily

Mounjaro is second obesity drug to be approved for use in England

Those with BMI of 35 and a comorbidity could be prescribed tirzepatide and Nice says it is more effective than Wegovy

The Guardian - UK

JPMorgan Forecast Over 85% Upside for Two Biopharma Stocks Targeting Obesity and Chronic Conditions

The two biopharma firms have developed drug candidates to treat autoimmune and pulmonary diseases. They have demonstrated good safety profiles and efficacy in various stages of clinical trials.

International Business Times UK

Having Obesity For 10 Years Or More Increases Risk Of Heart Attacks, Stroke: Study

Researchers discovered that being obese for 10 or more years significantly increases the risk for individuals under the age of 50.

Medical Daily

31% of Australians are obese – is Ozempic a healthy solution? A GP considers Johann Hari’s inside take on a ‘mass experiment’

Obesity levels for adults have hit 26% in Britain and 42.5% in the United States, journalist Johann Hari writes in his new book, Magic Pill. In Australia, recent data shows we’re somewhere in the middle: 31%.

The Conversation

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Cancer rates among under-50s in UK have risen 24% since 1995, figures show

Increase sharper than in any age group and is likely to be linked to soaring obesity levels, junk food and inactivity, say experts

The Independent UK

Being obese for a decade ‘puts people at greater risk of heart attack or stroke’

Living with obesity for 10 years is associated with an up to 60% increase in the risk of these conditions, scientists said.

The Independent UK

Is intermittent fasting better than counting calories? Maybe not, but you might stick with it

Intermittent fasting, where people eat what they want, but only during certain daily windows of time, has skyrocketed in popularity in recent years

GoodToKnow

How does too much screen time affect a child's development? We speak to experts about six ways screens impact growing up

Research has shown that screen time inhibits young children's ability to read faces and learn social skills... let's look a little deeper

Get all your
news in one place.

100’s of premium titles.
One news app.

Salon

"Super Size Me" at 20: A complex legacy

The iconic documentary turned 20 this month — the same month Oprah and "South Park" released weight loss specials

Dynamite News

Semaglutide ingredient can help protect kidney function in people with obesity

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been shown in the SELECT Trial to be effective in preventing the loss of kidney function in people who are overweight or obese and have established cardiovascular disease but do not have diabetes. Read further on Dynamite News:

Pedestrian.tv

9 Wild Moments From The New South Park Special About Ozempic: From Murderous Mums To Ear Shitting

South Park: The End Of Obesity about Ozempic has finally landed on Paramount+ and it's bonkers. Here are the top 9 mind-blowing moments.

Salon

Lizzo gratified by South Park name check

In the "End of Obesity" special, South Park residents want the latest semaglutides, but there's a cheaper option

Dynamite News

Study sheds more light on ability of cancer drug to lower blood sugar

The efficacy of a medication to prevent liver fat accumulation--a condition that frequently coexists with obesity and can result in dangerous fatty liver disease--has been further explored by researchers at the University of Oklahoma. Read further on Dynamite News:

The Guardian - UK

Weight-loss jabs shouldn’t be quick-fix solution for governments, says expert

Obesity prevention is cheaper long-term option, says Cambridge professor, with focus on dietary advice and exercise plans

International Business Times UK

Ark Invest CEO Cathie Wood Boosts Stake in Firms Making Breakthroughs in Gene Editing, AI Drug Development, and Obesity Drugs

Cathie Wood splurged millions in biotech this year on strong clinical progress, AI adoption, sales growth, wider outreach, and steady product pipelines.

1 … 7 8 9 10

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.